Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
EBITDA Margin: 23.5%, adjusted to 24.8% excluding a onetime provision. Gross Profit Margin: 53.6%, adjusted to 54.1% excluding a onetime provision. SG&A Spend: INR2,692 crores (USD300 million), 31% of revenue. R&D Spend: INR615 crores (USD68 million), 7% of revenues. Profit Before Tax: INR1,543 crores (USD172 million), 17.7% of revenue. Effective Tax Rate: Profit After Tax: INR1,210 crores (USD135 million), 13.9% of revenue. Diluted EPS: INR14.52. Operating Working Capital: INR14,142 crores (USD1.57 billion). CapEx Cash Outflow: INR669 crores (USD75 million). Free Cash Flow: INR374 crores (USD42 million). Net Cash Surplus: INR3,069 crores (USD342 million). North America Generics Revenue: USD338 million, a decline of 16% year on year. European Generics Revenue: USD140 million, a growth of 4% year on year. Emerging Markets Revenue: INR1,896 crores, a growth of 32% year on year. India Business Revenue: INR1,603 crores, a growth of 19% year on year. PSAI B
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]Seeking Alpha
- Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]Seeking Alpha
- Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "buy (b-)" rating to a "hold (c+)" rating.MarketBeat
RDY
Earnings
- 1/22/26 - Beat
RDY
Sec Filings
- 1/28/26 - Form 6-K
- 1/26/26 - Form 6-K
- 1/22/26 - Form 6-K
- RDY's page on the SEC website